Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline
LA Korde, MR Somerfield, LA Carey… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
Evaluation of racial/ethnic differences in treatment and mortality among women with triple-negative breast cancer
Importance To our knowledge, there is no consensus regarding differences in treatment and
mortality between non-Hispanic African American and non-Hispanic White women with triple …
mortality between non-Hispanic African American and non-Hispanic White women with triple …
[HTML][HTML] Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic …
Abstract Meta-analysis of> 87,000 patients demonstrates that patients with invasive lobular
carcinoma of the breast are far less likely to achieve pCR of the breast or axilla compared to …
carcinoma of the breast are far less likely to achieve pCR of the breast or axilla compared to …
Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database
ML Plasilova, B Hayse, BK Killelea, NR Horowitz… - Medicine, 2016 - journals.lww.com
The aim of this study was to determine the features of triple-negative breast cancer (TNBC)
using a large national database. TNBC is known to be an aggressive subtype, but national …
using a large national database. TNBC is known to be an aggressive subtype, but national …
Racial disparities in breast cancer: from detection to treatment
Abstract Purpose of Review Update on current racial disparities in the detection and
treatment of breast cancer. Recent Findings Breast cancer remains the leading cause of …
treatment of breast cancer. Recent Findings Breast cancer remains the leading cause of …
BRE12-158: A postneoadjuvant, randomized phase II trial of personalized therapy versus treatment of physician's choice for patients with residual triple-negative …
PURPOSE Patients with triple-negative breast cancer (TNBC) with residual disease after
neoadjuvant chemotherapy (NAC) have high risk of recurrence with prior data suggesting …
neoadjuvant chemotherapy (NAC) have high risk of recurrence with prior data suggesting …
Racial disparities in pathological complete response among patients receiving neoadjuvant chemotherapy for early-stage breast cancer
F Zhao, M Miyashita, M Hattori, T Yoshimatsu… - JAMA network …, 2023 - jamanetwork.com
Importance Among patients with breast cancer, inconsistent findings have been published
on racial disparities in achieving pathologic complete response (pCR) after neoadjuvant …
on racial disparities in achieving pathologic complete response (pCR) after neoadjuvant …
Time to treatment: measuring quality breast cancer care
AC Polverini, RA Nelson, E Marcinkowski… - Annals of surgical …, 2016 - Springer
Background To optimize breast cancer care, several organizations have crafted guidelines
to define best practices for treating breast cancer. In addition to recommended …
to define best practices for treating breast cancer. In addition to recommended …
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women
T O'Meara, A Safonov, D Casadevall, T Qing… - Breast cancer research …, 2019 - Springer
Abstract Purpose African-American (AA) patients with triple-negative breast cancer (TNBC)
are less likely to achieve pathologic complete response from neoadjuvant chemotherapy …
are less likely to achieve pathologic complete response from neoadjuvant chemotherapy …
[HTML][HTML] Predictors of pathological complete response to neoadjuvant chemotherapy in Iranian breast cancer patients
P Sasanpour, S Sandoughdaran… - Asian Pacific journal …, 2018 - ncbi.nlm.nih.gov
Background: Achievement of pathologic complete response (pCR) in breast cancer patients
receiving neoadjuvant chemotherapy (NAC) is associated with both overall survival and …
receiving neoadjuvant chemotherapy (NAC) is associated with both overall survival and …